Revolution Medicines’ daraxonrasib delivered broadly strong survival and disease-control results in metastatic pancreatic cancer, with detailed interim data presented at ASCO. In the Phase 3 trial evaluating the drug in patients with prior therapy and RAS G12 mutation–driven tumors, Revolution said overall survival nearly doubled versus standard chemotherapy across the overall population. Revolution reported a median overall survival of 13.2 months for daraxonrasib versus 6.6 months for chemotherapy among patients with RAS G12 mutations, while the all-treated comparison showed 13.2 months versus a 6.7-month chemotherapy median. The company also said the objective results on progression measures were similarly pronounced. Investigators described the data as “landscape-changing,” including the claim that the median overall survival exceeded one year for any pancreatic cancer population in a clinical trial. Revolution also began shipping the experimental drug under an FDA-authorized early access program, signaling rapid movement toward patient access while regulatory steps remain pending.